Biopharma · FDA Approvals · Stock
VIR Vir Biotechnology
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and …
Catalyst calendar
Dated catalysts for VIR, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for VIR, newest first.
Instant stream — events appear as soon as they are filed.
No events yet.
Peers by market cap
Companies in the same sector closest to VIR in market value.
IINVAInnovivaMarket cap $1.7B · 1 tracked drug
RAPPRapport TherapeuticsMarket cap $1.8B · 1 tracked drug · 3 upcoming catalystsOOBXObsidian TherapeuticsMarket cap $1.7B
ATAIAtaiBeckleyMarket cap $1.8B · 1 tracked drug · 1 upcoming catalyst
NUVBNuvation BioMarket cap $1.8B · 1 tracked drug · 4 upcoming catalysts
TSHATaysha GeneMarket cap $1.8B · 1 tracked drug · 3 upcoming catalysts
NRIXNurix TherapeuticsMarket cap $1.7B · 1 tracked drug · 3 upcoming catalysts
NTLAIntelliaMarket cap $1.8B · 2 tracked drugs · 2 upcoming catalysts
RAPPRapport TherapeuticsMarket cap $1.8B · 1 tracked drug · 3 upcoming catalystsOOBXObsidian TherapeuticsMarket cap $1.7BATAIAtaiBeckleyMarket cap $1.8B · 1 tracked drug · 1 upcoming catalystNUVBNuvation BioMarket cap $1.8B · 1 tracked drug · 4 upcoming catalystsTSHATaysha GeneMarket cap $1.8B · 1 tracked drug · 3 upcoming catalystsNRIXNurix TherapeuticsMarket cap $1.7B · 1 tracked drug · 3 upcoming catalystsNTLAIntelliaMarket cap $1.8B · 2 tracked drugs · 2 upcoming catalysts